Ketogenic diet (KD) is widely used for drug-resistant epilepsy (DRE). The study was designed to evaluate one of the risk factors for development of renal calculi with KD.
Twenty patients with DRE on Modified Atkins diet (MAD) were subjected to full history and laboratory investigations, including microscopic urine analysis, urinary calcium after overnight fasting, and calcium/creatinine ratio, as well as pelviabdominal ultrasound. Frequency and severity of seizures assessed by Chalfont severity score were recorded. All assessment measures were repeated after 3 and 6 months of KD therapy.
There were significant reductions in both frequency and severity of seizures, yet 2 patients (10%) developed renal stones after 6 months on KD. Gross hematuria was reported in 1 of those 2 patients (50%), but microscopic hematuria was detected in both patients. The urine calcium and the urine calcium/creatinine ratio were elevated in both patients having renal calculi after 6 months.
KD increases the risk of renal stones with hypercalciuria among the causes. We recommend initiation of prophylactic measures once KD is commenced by maximizing fluid intake and urine alkalinization with regular urinary studies including calcium/creatinine ratio and renal ultrasound for patients with symptoms.
KD has been increasingly used in epilepsy management and beyond. The potential side effects of such diet should be highlighted while valuing the merits.
KD increases the risk of renal stones because of hypercalciuria among other causes.
We recommend initiation of prophylactic measures once KD is commenced by maximizing fluid intake and urine alkalinization with estimation of urinary calcium/creatinine ratio and renal ultrasound in patients with relevant symptoms.
Subscribe to Journal
Get full journal access for 1 year
only $9.15 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Kwan, P. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51, 1069–1077 (2010).
Lutas, A. & Yellen, G. The ketogenic diet: metabolic influences on brain excitability and epilepsy. Trends Neurosci. 36, 32–40 (2013).
Sampath, A., Kossoff, E. H., Furth, S. L., Pyzik, P. L. & Vining, E. P. Kidney stones and the ketogenic diet: risk factors and prevention. J. Child. Neurol. 22, 375–378 (2007).
Freeman, J. M., Kossoff, E. H., Freeman, J. B., & Kelly, M. T. The Ketogenic Diet: A Treatment for Children and Others with Epilepsy 4th edn (Demos Medical Publishing, 2007).
Furth, S. L. et al. Risk factors for urolithiasis in children on the ketogenic diet. Pediatr. Nephrol. 15, 125–128 (2000).
Beleza, P. Refractory epilepsy: a clinically oriented review. Eur. Neurol. 62, 65–71 (2009).
Fisher, R. S. The new classification of seizures by the International League Against Epilepsy 2017. Curr. Neurol. Neurosci. Rep. 17, 48 (2017).
Duncan, J. S. & Sander, J. W. The Chalfont Seizure Severity Scale. J. Neurol. Neurosurg. Psychiatry 54, 873–876 (1991).
Kossoff, E. H. et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia 50, 304–317 (2009).
Bolenz, C., Schroppel, B., Eisenhardt, A., Schmitz-Drager, B. J. & Grimm, M.-O. The INVESTIGATION OF HEMAturia. Dtsch. Arztebl. Int. 115, 801–807 (2018).
Groleau, V., Schall, J. I., Stallings, V. A. & Bergqvist, C. A. Long-term impact of the ketogenic diet on growth and resting energy expenditure in children with intractable epilepsy. Dev. Med. Child. Neurol. 56, 898–904 (2014).
Tagliabue, A., Bertoli, S., Trentani, C., Borrelli, P. & Veggiotti, P. Effects of the ketogenic diet on nutritional status, resting energy expenditure, and substrate oxidation in patients with medically refractory epilepsy: a 6-month prospective observational study. Clin. Nutr. 31, 246–249 (2012).
Herrero, J. R. et al. Safety and effectiveness of the prolonged treatment of children with a ketogenic diet. Nutrients 12, 306 (2020).
Freeman, J. M. et al. A blinded, crossover study of the ketogenic diet. Epilepsia 50, 322–325 (2009).
Mirjavadi, S. A. et al. Efficacy of the ketogenic diet as a therapy for intractable epilepsy in children. Iran. J. Child. Neurol. 4, 27–36 (2010).
Hallbook, T. et al. Effectiveness of the ketogenic diet used to treat resistant childhood epilepsy in Scandinavia. Eur. J. Paediatr. Neurol. 19, 29–36 (2015).
El-Rashidy, O. F. et al. Modified Atkins diet vs classic ketogenic formula in intractable epilepsy. Acta Neurol. Scand. 128, 402–408 (2013).
Herzberg, G. Z., Fivush, B. A., Kinsman, S. L. & Gearhart, J. P. Urolithiasis associated with the ketogenic diet. J. Pediatr. 117, 743–745 (1990).
Freeman, J. M. et al. The efficacy of the ketogenic diet—1998: a prospective evaluation of intervention in 150 children. Pediatrics 102, 1358–1363 (1998).
Suo, C. et al. Efficacy and safety of the ketogenic diet in Chinese children. Seizure 22, 174–178 (2013).
McNally, M. A., Pyzik, P. L., Rubenstein, J. E., Hamdy, R. F. & Kossoff, E. H. Empiric use of oral potassium citrate reduces symptomatic kidney stone incidence with the ketogenic diet. Pediatrics 124, e300–e304 (2009).
Kielb, S., Koo, H. P., Bloom, D. A. & Faerber, G. J. Nephrolithiasis associated with the ketogenic diet. J. Urol. 164, 464 (2000).
Choi, J. N. et al. Renal stone associated with the ketogenic diet in a 5-year old girl with intractable epilepsy. Yonsei Med. J. 51, 457–459 (2010).
The authors declare no competing interests.
Ethics approval and consent to participate
Ethical committee approval was obtained, and the parents or caregivers of each patient gave an informed consent before participating in the study.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Nassar, M.F., El-Rashidy, O.F., Abdelhamed, M.H. et al. Modified Atkins diet for drug-resistant epilepsy and the risk of urolithiasis. Pediatr Res (2021). https://doi.org/10.1038/s41390-021-01732-y